Marcello Maugeri‐Saccà

Author

Also Known As

Konstantin Bräutigam, M Maugeri Saccà, M Maugeri-Saccà, M. Maugeri-Sacca, M. Maugeri-Saccà, Marcello Maugeri-Sacc, Marcello Maugeri-Sacca, Marcello Maugeri-Saccà, Marcello Maugeri‐Saccà, Maugeri-Saccà, Marcello

157

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Università Cattolica del Sacro Cuore University of Chieti-Pescara Istituti di Ricovero e Cura a Carattere Scientifico Sapienza University of Rome

About

Marcello Maugeri‐Saccà is an author at National Cancer Institute specializing in medicine, tumor biology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	1.7K
2	Cell Biology	10	10	1.2K
3	Health Sciences	5	5	769
4	Natural Sciences	1	1	60
5	Public Health	1	1	14

Marcello Maugeri‐Saccà

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells Monica Bartucci, Rosanna Dattilo, Chiara Moriconi, Oncogene Metastatic ActivityBreast OncologyMedicineStem Cell ResearchCell Proliferation	2014	359
Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer Maria Musumeci, Valeria Coppola, Antonio Addario, Oncogene UrologyMedicineCancer BiologySmall RnaProstatic Disease	2011	240
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden Daniele Marinelli, Marco Mazzotta, Stefano Scalera, Annals of Oncology MedicineLung AdenocarcinomaImmunologyPathologyCancer Genomics	2020	218
Cancer Stem Cells and Chemosensitivity Marcello Maugeri‐Saccà, Paolo Vigneri, Ruggero De Maria Clinical Cancer Research Developmental BiologyCellular SubpopulationMedicineStem Cell ToxicologyCancer Cell Biology	2011	206
Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy Monica Bartucci, Susanne Svensson, Paolo Romania, Cell Death and Differentiation Nsclc Stem CellsDifferentiated Nsclc CellsCancer Stem CellPathologyTumor Biology	2011	176
BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial–mesenchymal transition Valeria Coppola, Maria Musumeci, Michele Patrizii, Oncogene UrologyMedicineLuminal Markers ExpressionBtg2 LossProstatic Disease	2012	108
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells Gwenola Manic, Michele Signore, Antonella Sistigu, Gut	2017	100
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma Maria Elena Pisanu, Marcello Maugeri‐Saccà, Luigi Fattore, Journal of Experimental & Clinical Cancer Research	2018	86
KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy Stefano Scalera, Marco Mazzotta, Giacomo Corleone, Journal of Thoracic Oncology Tp53 Frame GenomicCancer ImmunosurveillanceLung AdenocarcinomaImmunologyPathology	2021	76
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study Giulia Bon, Laura Pizzuti, Valentina Laquintana, Journal of Experimental & Clinical Cancer Research	2020	72

Page 1